Ronald E. Bruehlman - 08 Nov 2025 Form 4 Insider Report for GoodRx Holdings, Inc. (GDRX)

Reporting relationship: Director
Issuer ticker: GDRX
Reported as of: 08 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Nov 2025, 17:13:45 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Gracye Cheng, Attorney-in-Fact for Ronald E Bruehlman

Key filing fact

Ronald E. Bruehlman filed Form 4 for GoodRx Holdings, Inc. (GDRX) on 10 Nov 2025.

Key facts

This page summarizes Ronald E. Bruehlman's Form 4 filing for GoodRx Holdings, Inc. (GDRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Nov 2025, 17:13.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001604076 Primary reporting owner

Bruehlman Ronald E

Relationship: Director
Address: C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD, SANTA MONICA
Signature: /s/ Gracye Cheng, Attorney-in-Fact for Ronald E Bruehlman
Signature date: 10 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GDRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +21,691
Change %: +24%
Price
Shares after: 111,025
Date: 08 Nov 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GDRX transaction Derivative

Deferred Stock Unit

Options Exercise

Transaction value: $0
Shares: -21,691
Change %: -33%
Price: $0.000000
Shares after: 43,384
Date: 08 Nov 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 21,691
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The deferred stock unit award vested as to one-third of the shares underlying the award on November 8, 2025. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Class A common stock.